Article Text

PDF
Prognostic value of stromal tumour infiltrating lymphocytes and programmed cell death-ligand 1 expression in breast cancer
  1. António Polónia1,2,3,4,
  2. Regina Pinto1,2,3,
  3. Jorge F Cameselle-Teijeiro5,
  4. Fernando C Schmitt1,2,3,4,6,
  5. Joana Paredes1,2,4
  1. 1Epithelial Interactions in Cancer (EPIC), i3S—Instituto de Investigação e Inovação em Saúde, University of Porto, Porto, Portugal
  2. 2Ipatimup, Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal
  3. 3Department of Pathology, Ipatimup Diagnostics, Ipatimup, University of Porto, Porto, Portugal
  4. 4FMUP, Faculty of Medicine, University of Porto, Porto, Portugal
  5. 5Complexo Hospitalar Universitario de Vigo (CHUVI), Vigo, Spain
  6. 6Laboratoire National de Santé, Dudelange, Luxembourg
  1. Correspondence to Dr Joana Paredes, Epithelial Interactions in Cancer Group, Instituto de Investigação e Inovação em Saúde (i3S), Rua Alfredo Allen 208, Porto 4200-135, Portugal; jparedes{at}ipatimup.pt

Abstract

Aim The present work aims to evaluate the presence of stromal tumour-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PDL1) expression in breast carcinomas and their correlation with available clinicopathological features.

Methods Two independent series of invasive breast cancer (IBC), one including ductal carcinoma in situ (DCIS) pair-matched cases, were selected, and quantification of TILs was accomplished in each case. Immunohistochemistry was also performed to evaluate the expression of PDL1.

Results In both cohorts evaluated, increased stromal TILs and PDL1 expression were present in about 10% of IBCs, being significantly associated with each other and both with grade 3 and triple-negative subtype. We observed a similar distribution of stromal TILs and PDL1 expression between DCIS and IBC. Finally, we observed that increased stromal TILs and PDL1 expression were significantly associated with cancer stem cell (CSC) markers, basal cell markers and vimentin expression. Interestingly, in IBC cases with vimentin expression, increased stromal TILs, as well as decreased PDL1 expression, disclosed a better clinical outcome, independently of the main classical BC prognostic factors.

Conclusions We have confirmed the association of stromal TILs and PDL1 expression with aggressive forms of BC and that both are already found in in situ stages. We also showed that stromal TILs and PDL1 expression are associated with clinical outcome in cases enriched for a mesenchymal immunophenotype. We describe for the first time a close relationship between CSC markers and PDL1 expression.

  • BREAST CANCER
  • TUMOUR IMMUNITY
  • TUMOUR MARKERS
  • CANCER STEM CELLS

Statistics from Altmetric.com

Footnotes

  • Handling editor Cheok Soon Lee

  • Contributors Conception and design: AP and JP; Development of methodology: RP; Acquisition of data (provided and managed breast carcinoma cases): AP and JFC-T; Analysis and interpretation of data: AP; Writing, review and/or revision of the manuscript: AP, FCS and JP. All authors read and approved the final manuscript.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.